Promoter CpG‐Site Methylation of the KAI1 Metastasis Suppressor Gene Contributes to Its Epigenetic Repression in Prostate Cancer

• Published in: The Prostate Vol. 77; no. 4; pp. 350 - 360
• Main Authors: Lee, Jaeseob, Lee, Moon‐Sung, Jeoung, Doo‐Il, Kim, Young‐Myeong, Lee, Hansoo
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.03.2017
• Subjects: Base Sequence; Cell Line, Tumor; CpG Islands - physiology; DNA methylation; epigenetic regulation; Epigenetic Repression - physiology; Genes, Tumor Suppressor - physiology; Humans; KAI1; Kangai-1 Protein - genetics; Kangai-1 Protein - metabolism; Male; Promoter Regions, Genetic - physiology; prostate cancer; Prostatic Neoplasms - genetics; Prostatic Neoplasms - metabolism; DNA methylation; prostate cancer; KAI1; epigenetic regulation
• ISSN: 0270-4137; 1097-0045
• DOI: 10.1002/pros.23274

BACKGROUND Repression of the KAI1 metastasis suppressor gene is closely associated with malignancy and poor prognosis in many human cancer types including prostate cancer. Since gene repression in human cancers frequently results from epigenetic alterations by DNA methylation and histone modifications, we examined whether the KAI1 gene becomes silenced through these epigenetic mechanisms in prostate cancer. METHODS KAI1 mRNA and protein levels were determined by RT‐PCR and immunoblotting analyses, respectively. Methylation status of the KAI1 promoter DNA in prostate cancer cell lines and tissues was evaluated by methylation‐specific PCR analysis of bisulfite‐modified genomic DNAs. Methylated CpG sites in the KAI1 promoter were identified by sequencing the PCR clones of the bisulfite‐modified KAI1 promoter DNA. KAI1 protein levels in human prostate cancer tissue samples were examined by immunofluorescence staining of the tissues with an anti‐KAI1 antibody. RESULTS Among the three human prostate cancer cell lines examined, PC3 and DU145 cells exhibited markedly decreased levels of KAI1 mRNA and protein as compared to LNCaP cells, even though the exogenous KAI1 promoter not being methylated was normally functional in all these cell lines. Treatment of the low KAI1‐expressing cell lines with a demethylating agent, 5′‐aza‐2′‐deoxycytidine, significantly elevated KAI1 expression levels, implicating the involvement of DNA methylation in KAI1 downregulation. Methylation of CpG islands within the KAI1 promoter region was observed in the low KAI1‐expressing cells, but not in the high KAI1‐expressing cells. Also, methyl CpG‐binding proteins such as MBD2 and MeCP2 were complexed to the KAI1 promoter in the low KAI1‐expressing cells. Bisulfite sequencing analysis identified the intensively methylated CpG residues in the KAI1 promoter clones derived from prostate cancer cells and tissues with no or low KAI1 expression. As in prostate cancer cell lines, prostate cancer tissues from patients also displayed a negative association between KAI1 expression levels and methylation status of the KAI1 promoter. CONCLUSIONS The present data suggest that the KAI1 gene might be repressed by epigenetic alterations through the promoter CpG‐site methylation during prostate cancer progression. This epigenetic mechanism could provide a clue for understanding how the KAI1 gene was silenced in metastatic prostate cancers. Prostate 77: 350–360, 2017. © 2016 Wiley Periodicals, Inc.